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Several porcine circovirus type 2 (PCV2) vaccines are now commercially available and have been shown to
be effective at decreasing the occurrence of porcine circovirus-associated disease (PCVAD). Many herds are
coinfected with PCV2 and porcine reproductive and respiratory syndrome virus (PRRSV). Some producers and
veterinarians are concerned that if pigs are vaccinated for PCV2 at or near the time that they are typically
infected with PRRSV, the efficacy of the PCV2 vaccine will be compromised. The impact of PRRSV on PCV2
vaccination is unclear and has not been investigated under controlled conditions. The objective of the present
study was to determine whether the presence of PRRSV viremia has an effect on the efficacy of commercial
PCV2 vaccinations. Three-week-old PCV2-negative conventional pigs with passively derived anti-PCV2 anti-
bodies were either vaccinated with one of three commercial PCV2 vaccines or left nonvaccinated. A portion of
the pigs were infected with PRRSV 1 week prior to PCV2 vaccination. To determine vaccine efficacy, a PCV2
challenge was conducted at 8 weeks of age. PCV2 vaccination, regardless of PRRSV infection status at the time
of vaccination, was similarly effective in inducing an anti-PCV2 IgG response in the presence of maternally
derived immunity and in protecting the pigs from PCV2 challenge, as determined by a reduction in the level
of PCV2 viremia and a reduction in the prevalence and amount of PCV2 antigen in lymphoid tissues in
vaccinated pigs compared to nonvaccinated pigs. The results indicate that acute PRRSV infection at the time
of PCV2 vaccination has no adverse effect on PCV2 vaccine efficacy.
Porcine circovirus (PCV) type 2 (PCV2) is a single-stranded,
circular, nonenveloped DNA virus with an icosahedral symme-
try (6, 44). It has an ambisense genome of approximately 1.8 kb
and belongs to the family Circoviridae, members of which are
known to be very host specific and often associated with sub-
clinical infections (36, 45). PCV-associated disease (PCVAD),
first recognized in 1991 as postweaning multisystemic wasting
syndrome (PMWS) (15), has spread throughout the global
swine population. Besides the systemic presentation of PCV2
infection, other disease manifestations of PCVAD include re-
spiratory disease, enteritis in grow-finisher pigs, reproductive
failure, and porcine dermatitis and nephropathy syndrome
(PDNS) (27). Lymphoid depletion and granulomatous inflam-
mation in several organ systems are the hallmark lesions of
PCVAD (41).
Pigs concurrently infected with PCV2 and other pathogens
have a greater potential of developing clinical PCVAD (27). In
a retrospective study in South Korea, 76.2% (80/105) of pigs
suffering from porcine respiratory disease complex (PRDC)
were found to be coinfected with PCV2 and various other
pathogens, including porcine reproductive and respiratory syn-
drome virus (PRRSV), swine influenza virus (SIV), and por-
cine parvovirus (PPV) (18). In another investigation in the
United States, PRRSV was present in 51.9% of 484 cases of
systemic PCVAD and was the most frequent pathogen (34). In a
cross-sectional study performed with 583 conventionally reared
pigs of different ages, coinfections of PCV2 with PRRSV, SIV,
and Mycoplasma hyopneumoniae had the greatest effect on the
development of diseases in the early to late nursery phases (8).
In a case-control study of pigs with and without PCVAD, pigs
with concurrent PCV2 and PRRSV infections had a higher
odds ratio of developing PCVAD (35).
PRRSV is a single-stranded, positive-sense, enveloped RNA
virus that belongs to the family Arteriviridae, genus Arterivirus
(4). PRRSV primarily infects the monocyte/macrophage cell
line (11) via CD163 scavenger receptor and heparin sulfate and
sialoadhesin receptors (10, 46), which are also involved in the
primary defense of the innate immune system (9, 21). It causes
reproductive failure in pregnant sows and respiratory disease
in pigs of all ages and is also associated with neonatal diarrhea
(1, 3, 23, 37). Under experimental conditions, with concurrent
PRRSV and PCV2 infection in 1- to 2-day-old colostrum-
deprived (CD) pigs (2), 5-week-old PCV2-seropositive pigs
(38), or 3-week-old cesarean-derived colostrum-deprived (CD/
CD) pigs (16), more severe clinical disease and lesions as well
as enhanced replication and distribution of PCV2 were ob-
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served compared to the conditions for pigs inoculated with
PCV2 alone. These results suggest that immune modulation by
PRRSV may be a key factor in the development of PCVAD.
PRRSV can be transmitted transplacentally, resulting in in-
fected neonates, and PRRSV viremia may last for up to 154
days, with virus being detectable in tissues for up to 202 days
(20). PRRSV seroconversion and viremia typically occur dur-
ing the nursery phase of production. It is a common practice
for veterinarians and producers to adjust the timing of admin-
istration (delay or move earlier) of common vaccinations, such
as vaccination for M. hyopneumoniae (9), to avoid vaccine
failure associated with PRRSV-induced immunosuppression.
At present, no information exists on the efficacy of PCV2
vaccination in PRRSV viremic pigs. The objective of this study
was to determine the effect of PRRSV infection at the time of
PCV2 vaccination on PCV2 vaccine efficacy. Three currently
available commercial PCV2 vaccines were compared in the
conventional pig model using pigs with passively acquired anti-
PCV2 antibodies with or without experimental PRRSV infec-
tion.
MATERIALS AND METHODS
Animals and housing. Ninety-nine specific-pathogen-free (SPF) pigs were
weaned at 2 weeks of age from high-health sows free of PRRSV and SIV. PCV2
vaccination was not used in the breeding herd. The dams of the piglets used in
this study were not PCV2 viremic (negative for PCV2 DNA on serum evaluation)
but were positive for PCV2 antibody, as determined by PCV2 enzyme-linked
immunosorbent assay (ELISA) approximately 1 week before farrowing. Upon
arrival at the research facility at Iowa State University, the pigs were housed in
four separate rooms: the noninfected negative-control group and the group
infected with PRRSV alone were housed in separate rooms, and all other pigs
regardless of treatment group were randomly assigned to one of two rooms,
which each contained four pens. The pens were 2 m by 2.3 m in size, and each
one was equipped with one nipple drinker and a self feeder that contained a
complete feed ration free of animal proteins (excluding whey) and antibiotics
(Nature’s Made; Heartland Coop, IA).
Experimental design. The 99 pigs were randomly divided into 10 groups of 9
to 11 pigs in each group after arrival at the Iowa State University research
facility. The experimental design is summarized in Table 1. At 2 weeks of age, 51
out of 99 pigs were inoculated with PRRSV. At 3 weeks of age, portions of the
PRRSV-infected (n  29) and noninfected (n  29) pigs were vaccinated with
one of three commercially available vaccines, as described in Table 1. At 5 weeks
of age, 2 groups (n  20) were each given a booster dose of vaccines. At 10
weeks of age, 79 pigs were challenged with PCV2b. All pigs were necropsied at
13 weeks of age. Blood samples were collected from each group on the day of
arrival at the facility and weekly thereafter until necropsy. The serum samples
collected on the day of PCV2 challenge and at days postchallenge (dpc) 7, 14,
and 21 were tested for the presence and amount of PRRSV RNA by reverse
transcription (RT) real-time PCR and for PCV2 DNA by quantitative real-time
PCR. The experimental protocol was approved by the Iowa State University
Institutional Animal Care and Use Committee (IACUC; approval number 8-08-
6618-S).
PRRSV inoculation. At 2 weeks of age, 51 pigs (in the PRRSV-Fort Dodge
Animal Health (FDAH)-PCV2, PRRSV-Boehringer Ingelheim Vetmedica Inc.
(BIVI)-PCV2, PRRSV-Intervet-PCV2, PRRSV, and PRRSV-PCV2 groups)
were inoculated with approximately 105 50% tissue culture infective doses
(TCID50) of PRRSV isolate VR2385 as described previously (40). Each pig
received 2 ml of the PRRSV inoculum intranasally by slowly dripping 1 ml into
each nostril.
Vaccination. Three commercial vaccines were used in this experimental study.
At 3 weeks of age, pigs in the PRRSV-FDAH-PCV2 and FDAH-PCV2 groups
were vaccinated intramuscularly with 2 ml of Suvaxyn PCV2 vaccine (serial
number 1861220A; Fort Dodge Animal Health, Inc., Fort Dodge, IA). Similarly,
pigs in the PRRSV-BIVI-PCV2 and BIVI-PCV2 groups were vaccinated intra-
muscularly with 1 ml of Ingelvac CircoFLEX vaccine (serial number 309-136;
Boehringer Ingelheim Vetmedica Inc.) at 3 weeks of age. Pigs in the PRRSV-
Intervet-PCV2 and Intervet-PCV2 groups were vaccinated intramuscularly using
2 ml of Circumvent vaccine (serial number 02137920; Intervet Schering-Plough
Animal Health) at 3 and 5 weeks of age.
PCV2 challenge. At 10 weeks of age, pigs in groups PRRSV-FDAH-PCV2,
PRRSV-BIVI-PCV2, PRRSV-Intervet-PCV2, FDAH-PCV2, BIVI-PCV2, In-
tervet-PCV2, PRRSV-PCV2, and PCV2 were challenged with PCV2b. PCV2b
isolate NC16845 (31) was used at a dose of 104.5 TCID50 per ml. Each pig
received 2 ml intranasally and 2 ml intramuscularly.
Clinical evaluation. All the pigs were weighed on the day of arrival, the day of
vaccination (3 and 5 weeks of age), the day of challenge (10 weeks of age; 0 dpc),
and the day of necropsy (21 dpc); and the average daily weight gain (ADWG)
was calculated. Other clinical parameters were not evaluated.
Anti-PCV2 IgG antibodies. All serum samples collected prior to PCV2 chal-
lenge (2, 3, 4, 5, 6, 7, 8, 9, and 10 weeks of age) and at dpc 7, 14, and 21 were
tested using a SERELISA PCV2 Ab Mono blocking kit (Synbiotics Europe,
Lyon, France) according to the manufacturer’s instructions. Results were ex-
pressed as a sample-to-negative corrected (SNc) ratio. Samples were considered
positive for the presence of anti-PCV2 antibodies if the calculated SNc ratio
was less than or equal to 0.50, and they were considered negative if the SNc
ratio was greater than 0.50.
PCV2 DNA detection and quantification. The DNA from serum samples
collected at dpc 7, 14, and 21 was extracted using a QIAamp DNA minikit
(Qiagen, Valencia, CA). The DNA was tested for the presence and amount of
PCV2 DNA using a quantitative real-time PCR as described previously (33).
Anti-PRRSV IgG antibodies. Serum samples collected from pigs at 2 weeks of
age and at dpc 0 and 21 were tested for the presence of antibodies to PRRSV
(HerdChek X3 PRRS virus antibody test kit; IDEXX Laboratories Inc., West-
brook, MA). A sample-to-positive (S/P) ratio of equal to or greater than 0.4 was
considered a positive result.
PRRSV RNA detection and quantification. RNA extraction from serum sam-
ples collected at the day of PCV2 vaccination, 7 days after PCV2 vaccination, and
dpc, 0, 7, 14, and 21 from all the PRRSV-inoculated groups was performed using
a QIAamp viral RNA minikit (Qiagen). Detection and quantification of PRRSV
genomic RNA from the RNA extracts was achieved by real-time RT-PCR as
described previously (40).
Necropsy. All pigs were humanely euthanized by pentobarbital overdose
(Fatal-plus; Vortex Pharmaceutical, Ltd; Dearborn, MI) and necropsied at 13
weeks of age (21 dpc). The total amount of lung surfaces affected by macroscopic
lesions (ranging from 0 to 100%) (14) and size of lymph nodes, with scores
ranging from 0 (normal size) to 3 (four times the normal size) (32), were
estimated in a blinded fashion. Sections of liver, spleen, colon, kidney, lymph
nodes (mesenteric, superficial inguinal, tracheobronchial, and mediastinal),
ileum, tonsil, and thymus were collected at necropsy; fixed in 10% neutral-
buffered formalin; and processed routinely for histological examination.
Histopathology. Microscopic lesions were evaluated by a veterinary patholo-
gist (T.O.) blinded to the treatment groups. Sections of heart, liver, kidney,
ileum, and colon were evaluated for the presence of lymphohistiocytic inflam-
mation and were scored from 0 (none) to 3 (severe). Lung sections were scored
for the presence and severity of interstitial pneumonia, with scores ranging from
0 (normal) to 6 (severe, diffuse) (14). Lymphoid tissues, including lymph nodes,
tonsil, and spleen, were evaluated for the presence of lymphoid depletion, with
scores ranging from 0 (normal) to 3 (severe), and histiocytic inflammation and
replacements of follicles, with scores ranging from 0 (normal) to 3 (severe) (32).
IHC. Immunohistochemistry (IHC) staining for the detection of PCV2 antigen
was conducted on selected formalin-fixed and paraffin-embedded sections of
TABLE 1. Experimental design
Group designation No. ofpigs
PRRSV infection
(2 wk)
PCV2
vaccine
amt (ml)
Challenge
(10 wk)
3 wk 5 wk
PRRSV-FDAH-PCV2 10 PRRSV 2 PCV2
FDAH-PCV2 10 2 PCV2
PRRSV-BIVI-PCV2 10 PRRSV 1 PCV2
BIVI-PCV2 9 1 PCV2
PRRSV-Intervet-PCV2 10 PRRSV 2 2 PCV2
Intervet-PCV2 10 2 2 PCV2
PRRSV 11 PRRSV
PCV2 10 PCV2
PRRSV-PCV2 10 PRRSV PCV2
Negative controls 9
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lymph nodes (mesenteric, superficial inguinal, tracheobronchial, and mediasti-
nal), spleen, tonsil, and thymus using a rabbit polyclonal antiserum (42). PCV2
antigen scoring was done by a pathologist blinded to the treatment status of the
animals, with scores ranging from 0 (no signal) to 3 (abundant amount of PCV2
antigen) as described previously (32).
Overall lymphoid lesion score. The overall microscopic lymphoid lesion score,
which accounts for lymphoid depletion, histiocytic inflammation, and amount of
PCV2 antigen, was calculated as previously described (32).
Statistical analysis. Statistical analysis of the data was performed using JMP
software, version 8.0.1 (SAS Institute, Cary, NC). Summary statistics were cal-
culated for all groups to assess the overall quality of the data, including normal-
ity. Continuous data were analyzed using the one-way analysis of variance
(ANOVA). A P value of less than 0.05 was set as a statistically significant level
throughout this study. If an ANOVA was significant, pairwise testing using
Tukey’s adjustment was performed to assess specific group differences. Real-time
PCR results (number of copies per ml of serum) were log10 transformed prior to
statistical analysis. Percent reduction for PCR data was measured as follows:
100  [(100  mean log10 number of genomic copies/ml in the vaccinated
group)/(mean log10 number of genomic copies/ml in positive-control animals)].
Nonrepeated measures of necropsy and histopathology data were assessed using
a nonparametric Kruskal-Wallis one-way ANOVA. If this nonparametric
ANOVA test was significant (P  0.05), then pairwise Wilcoxon tests were used
to assess differences between groups. In order to determine differences in prev-
alence, a chi-square test was used.
RESULTS
ADWG. There were no significant (P  0.05) differences in
initial body weights among the groups of pigs at arrival in the
research facility. After PRRSV infection, between 2 and 3
weeks of age, the ADWG in PRRSV-infected pigs was signif-
icantly (P  0.05) lower than that in noninfected pigs (0.25 
0.01 kg versus 0.28  0.01 kg). Similarly, from 3 to 10 weeks of
age, the ADWG in PRRSV-infected pigs was significantly (P
0.0001) lower than that in noninfected pigs (0.66  0.01 kg
versus 0.77  0.01 kg). PCV2 vaccination had no effect on
ADGW, as there was no significant (P  0.05) difference
between the vaccinated and nonvaccinated groups from 3 to 10
weeks of age. The ADWG for the individual groups from the
time of PCV2 challenge until necropsy (10 to 13 weeks of age)
is summarized in Table 2. There was no significant (P  0.05)
difference between PRRSV-infected and noninfected pigs or
between vaccinated and nonvaccinated pigs. However, the
ADWG in PCV2-infected pigs was significantly (P  0.05)
lower than that in noninfected pigs (1.00  0.02 kg versus
1.08  0.05 kg).
Anti-PCV2 IgG antibody levels. At arrival, 95/99 pigs had
passively acquired PCV2 antibodies, with group mean SNc
ratios between 0.00 and 0.10 (Fig. 1), and no significant differ-
ences were observed among the different treatment groups.
The group mean PCV2 ELISA SNc ratios in vaccinated pigs
were significantly (P  0.0001) lower than those in nonvacci-
nated pigs between 5 weeks of age (vaccinated pigs, 0.22 
0.04; nonvaccinated pigs, 0.39  0.04) and 10 weeks of age
(vaccinated pigs, 0.06 0.02; nonvaccinated pigs, 0.51 0.04).
Significantly (P  0.05) higher SNc ratios (lower levels of
antibody) were observed in the BIVI groups than in the FDAH
and Intervet groups during the growing period; however, this
was independent of PRRSV status. At the day of PCV2 chal-
lenge at 10 weeks of age, 98% (58/59) of the vaccinated pigs
had detectable anti-PCV2 antibodies, whereas only 42.5% (17/
40) of the nonvaccinated pigs were seropositive. After PCV2
challenge (dpc 7, 14, and 21), vaccinated groups had signifi-
cantly (P  0.001) lower SNc ratios than nonvaccinated chal-
lenge pigs, which were independent of the product used or
PRRSV infection status at the time of vaccination and at 14
and 21 dpc.
Prevalence and amount of PCV2 DNA in serum. Pigs in the
negative-control group and in the PRRSV group remained
negative for PCV2 DNA throughout the study period. After
PCV2 challenge, PCV2 DNA was detected in the majority of
the nonvaccinated pigs at 7 (70%), 14 (100%), and 21 (100%)
dpc. Among the vaccinated pigs, PCV2 viremia was limited to
a few individual pigs (Table 3). Vaccination significantly (P 
0.05) reduced the amount of PCV2 DNA compared to that in
nonvaccinated pigs (Table 3). The mean reductions of PCV2
viremia in the serum at 21 dpc were 88.6% for FDAH-PCV2,
88.8% for BIVI-PCV2, 90.2% for Intervet-PCV2, 89.4% for
PRRSV-FDAH-PCV2, 66.8% for PRRSV-BIVI-PCV2, and
100% for PRRSV-Intervet-PCV2.
Anti-PRRSV IgG antibody levels. All pigs were negative for
anti-PRRSV antibodies at the start of the study at 2 weeks of
age (data not shown). All pigs that were not experimentally
infected with PRRSV remained seronegative for PRRSV until
the termination of the study at 13 weeks of age. At 10 weeks of
age (dpc 0), the mean PRRSV ELISA S/P ratio values were
2.30  0.11 for PRRSV-infected, non-PCV2-vaccinated pigs
(n  21) and 2.17  0.09 for PRRSV-infected, PCV2-vacci-
nated pigs (n  30), with no significant (P  0.05) difference
FIG. 1. Mean anti-PCV2 IgG antibody responses in the different
treatment groups following PCV2 challenge. PRRSV inoculation, the
first vaccination (Vac), challenge, and necropsy were performed at 2,
3, 10, and 13 weeks of age, respectively. Samples with an SNc ratio of
0.5 or greater are considered negative. Error bars indicate standard
errors.
TABLE 2. ADWG from 0 to 21 dpc
Group ADWG  SE (kg)a
PRRSV-FDAH-PCV2..................................................1.02 0.03A,B,C
FDAH-PCV2.................................................................0.96 0.03B,C
PRRSV-BIVI-PCV2 .....................................................1.12 0.04A,B
BIVI-PCV2 ....................................................................1.03 0.03A,B,C
PRRSV-Intervet-PCV2 ................................................0.99 0.05B,C
Intervet-PCV2 ...............................................................1.00 0.05A,B,C
PRRSV...........................................................................0.98 0.06B,C
PCV2 ..............................................................................0.91 0.05C
PRRSV-PCV2 ...............................................................0.98 0.06B,C
Negative controls ..........................................................1.21 0.06A
a Different superscripts (A, B, and C) within the same column represent
significant differences (P  0.05) between groups.
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existing between groups. Similarly, there was no significant
(P  0.05) difference in mean group PRRSV S/P ratios on dpc
21 between PCV2-vaccinated (1.78  0.11) and nonvaccinated
(2.08  0.13) pigs or between PCV2-challenged (1.87  0.10)
and nonchallenged (2.04  0.17) pigs.
Prevalence and amount of PRRSV RNA in serum. At the
time of PCV2 vaccination (7 days after PRRSV inoculation)
and 7 days after PCV2 vaccination (14 days after PRRSV
inoculation), 100% of the pigs in the PRRSV-challenged
groups were positive for PRRSV RNA in serum, with PRRSV
RNA loads ranging from 6.16 to 6.66 log10 copies/ml (Table 4).
From 0 to 21 dpc, low levels of PRRSV RNA were detected in
a few (1 to 3) pigs in all PRRSV-infected groups (Table 4). No
significant (P  0.05) differences were observed for PRRSV
prevalence or RNA loads among the different treatment
groups.
Macroscopic and microscopic lesions and PCV2 antigen in
lesions. Macroscopic lung lesions were characterized by failure
of the lungs to collapse and by focal-to-diffuse, mottled tan
areas of pneumonia. Vaccinated, PCV2-challenged pigs (n 
59) had significantly (P  0.05) lower mean lung scores than
nonvaccinated PCV2-infected pigs (n 20) (1.97 0.32 versus
3.95  1.00). Moreover, PRRSV-negative PCV2-challenged
pigs (n  39) had significantly (P  0.05) lower mean lung
scores than PRRSV-positive PCV2-challenged pigs (n  40)
(1.46 0.28 versus 3.45 0.62). There was no difference in the
severity of macroscopic lung lesions among vaccinated groups
(P  0.05). In the PRRSV-PCV2 group, 9/10 pigs had lymph
nodes of 2 to 3 times the normal size. In the remaining groups,
individual pigs (1 to 2 per group) had mildly enlarged lymph
nodes.
Microscopic lesions were characterized by mild to severe
lymphoid depletion and mild to moderate histiocytic replace-
ment in lymphoid tissues. Among vaccinated pigs, 83.3% (49/
59) had normal lymphoid tissues and 16.9% (10/59) had mild
lymphoid lesions (overall lymphoid score, 1 or 2). Nonvacci-
nated and PCV2-infected pigs however, had the following le-
sion distribution: 10% (2/20) had normal lymphoid tissues,
45% (9/20) had mild lymphoid lesions (score, 1, 2, or 3), 40%
(8/20) had moderate lymphoid lesions (score, 4, 5, or 6), and
5% (1/20) had severe PCV2-associated lesions (score, 7).
There was no difference in lesion severity between PRRSV-
infected and noninfected pigs.
PCV2 antigen was detected in 8/10 pigs in the PRRSV-
PCV2 group, 7/10 pigs in the PCV2 group, and 0/59 pigs in the
vaccinated groups; the differences were statistically significant
(P  0.05).
DISCUSSION
Various commercially available killed PCV2 vaccines are
being used worldwide, and their efficacies have been demon-
strated under both experimental conditions (13, 25, 29, 30, 40)
and field conditions (5, 12, 17, 19, 39). PCV2 vaccination is
recommended for usage in weaned pigs at about 3 weeks of age
or older. However, at this age many pigs derived from PRRSV-
positive breeding herds are infected with PRRSV, which is
thought to negatively impact PCV2 vaccine efficacy. In the
TABLE 3. PCV2 DNA-positive pigs among all pigs in each group at different days after PCV2 challenge
Group
No. of pigs PCV2 DNA positive/no. of pigs in group on the following days after PCV2 challengea:
7 14 21
PRRSV-FDAH-PCV2 1/10 (0.42 0.4)A 0/10 (0.00 0.0)A 0/10 (0.00  0.0)A
FDAH-PCV2 1/10 (0.38 0.4)A 0/10 (0.00 0.0)A 0/10 (0.00  0.0)A
PRRSV-BIVI-PCV2 2/10 (0.89 0.6)A 3/10 (1.56 0.8)B 2/10 (0.81  0.5)A
BIVI-PCV2 4/9 (1.98 0.8)AB 2/9 (0.92 0.6)BA 1/9 (0.41  0.4)A
PRRSV-Intervet-PCV2 0/10 (0.00 0.0)A 0/10 (0.00 0.0)A 0/10 (0.00  0.0)A
Intervet-PCV2 0/10 (0.00 0.0)A 0/10 (0.00 0.0)A 1/10 (0.36  0.4)A
PRRSV 0/11 (0.00  0.0)A 0/11 (0.00 0.0)A 0/11 (0.00  0.0)A
PCV2 7/10 (3.67  0.8)B 10/10 (6.69 0.4)C 10/10 (5.96  0.3)B
PRRSV-PCV2 7/10 (3.94 0.9)B 10/10 (7.22 0.2)C 10/10 (7.23  0.3)B
Negative controls 0/9 (0.00 0.0)A 0/9 (0.00 0.0)A,B 0/9 (0.00  0.0)A
a Different superscripts (A, B, and C) within the same column represent significant differences (P  0.05) in the mean amount of log10 PCV2 DNA between groups.
Values in parentheses represent the mean log10 number of PCV2 DNA copies  standard error for the group.
TABLE 4. PRRSV RNA-positive pigs among all pigs in each group for pigs experimentally inoculated with PRRSV 7 days prior to PCV2
vaccination and 8 weeks prior to PCV2 challenge
Group
No. of pigs PRRSV RNA positive/no. of pigs in group on the indicated days aftera:
PCV2 vaccination PCV2 challenge
0 7 0 7 14 21
PRRSV-FDAH-PCV2 10/10 (6.16 0.3) 10/10 (6.66  0.3) 0/10 (0.00 0.0) 1/10 (0.43  0.4) 2/10 (0.96 0.6) 0/10 (0.00 0.0)
PRRSV-BIVI-PCV2 10/10 (6.35 0.1) 10/10 (6.40  0.3) 0/10 (0.00  0.0) 1/10 (0.32 0.3) 2/10 (0.66  0.4) 2/10 (0.67 0.5)
PRRSV-Intervet-PCV2 10/10 (6.29 0.2) 10/10 (6.33  0.2) 2/10 (0.63  0.4) 1/10 (0.34 0.3) 3/10 (1.07  0.6) 2/10 (0.00 0.0)
PRRSV 11/11 (6.48 0.2) 11/11 (6.59  0.4) 0/11 (0.00  0.0) 1/11 (0.32 0.3) 1/11 (0.37  0.4) 0/11 (0.00 0.0)
PRRSV-PCV2 10/10 (6.44 0.3) 10/10 (6.29  0.4) 2/10 (0.69  0.5) 1/10 (0.28 0.3) 2/10 (0.83  0.6) 2/10 (0.79 0.5)
a Values in parentheses represent the mean log10 PRRSV RNA copies  standard error for the group.
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present study, we evaluated PCV2 vaccine efficacy in PRRSV-
positive conventional pigs by experimental inoculation with a
known virulent isolate of PRRSV (14, 24, 28). It is well-known
that PRRSV strains differ in virulence (28), and the results of
this study may be different with other PRRSV challenge iso-
lates.
Increased PCV2 replication and clinical PCVAD were ob-
served in pigs experimentally coinfected with PRRSV and
PCV2 (2, 16, 38). Although PRRSV-infected pigs had signifi-
cantly increased macroscopic lung lesions in the present study,
significant differences in the severity of microscopic lesions or
amount of PCV2 antigen were not observed in PCV2-chal-
lenged pigs. A possible explanation for the discrepancy in ob-
servations is the difference in timing of pathogen administra-
tion: in the current study, the pigs were infected with PRRSV
at 2 weeks of age, followed by PCV2 challenge at 10 weeks of
age, whereas previously, coinfections were conducted at the
same time (16) or within an interval of a few days (2, 38) and
were done in younger pigs (1 to 35 days of age).
Although PCV2 vaccines are in general very effective, cases
of apparent vaccine failures continue to occur. Vaccine failures
under field conditions may be due to many reasons, including
failure to follow the proper administration protocols and to use
the recommended dose of the vaccines (30). The field strains
might be different from the vaccine strains, and the breed of
the pigs can also influence the outcome of PCVAD (22, 30).
The presence of high levels of passively derived anti-PCV2
antibodies at the time of vaccination has also been associated
with decreased vaccine efficacy and vaccine failures. Experi-
mental proof of this is lacking to date, as available research
results indicate no adverse effect of maternally derived immu-
nity on PCV2 vaccine efficacy (13, 29, 40). Similarly, the results
of the current study indicate that PCV2 vaccination in the face
of high levels of passively derived anti-PCV2 immunity was
effective in inducing a humoral immune response. At 10 weeks
of age, a significant higher prevalence of seropositive pigs was
found in the vaccinated group than in the nonvaccinated con-
trol group.
Several studies have investigated the effect of PRRSV
infection on vaccine efficacy but provided conflicting results.
PRRSV infection at the time of classical swine fever virus
vaccination significantly inhibited the host immune response
and resulted in vaccination failure after subsequent exposure
to classical swine fever virus (7, 43). For pseudorabies virus
vaccination, although PRRSV infection affected the duration
of the T-lymphocyte response, it did not inhibit the efficacy of
the vaccine, which was capable of inducing protective immu-
nity (7). In the present study, our data revealed that all the
commercial vaccines used in this study were able to induce a
protective immunity against PCV2 in the face of PRRSV in-
fection at the time of vaccination. The difference in the exper-
imental results might be due to different timings of infection
with PRRSV, vaccination, and challenge. In the present study,
pigs were challenged 5 weeks (two dose administrations) to 7
weeks (one dose administration) after vaccination, in contrast
to a study where challenge occurred 3 weeks after initial vac-
cination (43).
In a previous study (26), we found that PCV2 infection had
adverse effects on the efficacy of a modified live virus (MLV)
PRRSV vaccine. The different effects of PRRSV and PCV2
infection on the efficacy of vaccines may be due to the different
mechanisms that these two viruses use to induce immunosup-
pression (replication in macrophages versus lymphoid deple-
tion), which are still not completely understood, and the types
of vaccine (attenuated live versus inactivated) tested.
All PCV2 vaccines used, regardless of PRRSV infection
status at the time of vaccination, were able to suppress PCV2
replication after PCV2 challenge, as demonstrated by signifi-
cantly reduced levels of PCV2 viremia and significantly re-
duced amounts of PCV2 antigen in lymphoid tissues. The
results of our study demonstrated that by 21 dpc there was no
difference in the prevalence of PCV2 DNA in vaccinated
groups regardless of PRRSV infection status at the time of
vaccination or the vaccine product used. We conclude that
prior PRRSV infection does not have an adverse effect on
commercial PCV2 vaccination in conventional growing pigs
and that pigs can be effectively immunized against PCV2 in the
face of maternal antibodies.
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